ストックスクリーナーアプリを入手
2.44
2.95%
0.07
前日終値:
$2.37
開ける：
$2.39
24時間の取引高:
2.26M
Relative Volume:
1.12
時価総額：
$201.42M
収益：
$78.12M
当期純損益:
$-153.22M
株価収益率:
-0.8243
EPS:
-2.96
ネットキャッシュフロー:
$-136.90M
1週間 パフォーマンス:
-8.27%
1か月 パフォーマンス:
-25.84%
6か月 パフォーマンス:
-59.47%
1年 パフォーマンス:
-76.74%
1日の値動き範囲:
$2.33
$2.535
1週間の範囲:
$2.30
$2.69
52週間の値動き範囲:
$2.30
$11.69
Editas Medicine Inc Stock (EDIT) Company Profile
EDIT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| EDIT | 2.44 | 201.42M | 78.12M | -153.22M | -136.90M | -2.96 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-05-09 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | アップグレード | Citigroup | Neutral → Buy |
| 2023-10-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | アップグレード | Stifel | Hold → Buy |
| 2023-06-12 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 開始されました | Citigroup | Neutral |
| 2022-12-06 | 再開されました | Credit Suisse | Neutral |
| 2022-11-18 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 開始されました | BofA Securities | Neutral |
| 2021-10-19 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-09-24 | 開始されました | Stifel | Hold |
| 2021-09-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-08-09 | アップグレード | Truist | Hold → Buy |
| 2021-08-05 | アップグレード | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 開始されました | Goldman | Sell |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-26 | ダウングレード | Truist | Buy → Hold |
| 2021-01-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 開始されました | Robert W. Baird | Underperform |
| 2020-06-18 | 再開されました | SunTrust | Buy |
| 2020-02-21 | 開始されました | Wells Fargo | Equal Weight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-10-10 | 開始されました | Guggenheim | Neutral |
| 2018-09-21 | 開始されました | Raymond James | Outperform |
| 2018-05-15 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-02-13 | 開始されました | CLSA | Underperform |
| 2018-01-23 | アップグレード | SunTrust | Hold → Buy |
| 2017-07-14 | 開始されました | SunTrust | Hold |
| 2017-03-28 | 開始されました | Chardan Capital Markets | Buy |
| 2016-08-10 | アップグレード | Jefferies | Hold → Buy |
| 2016-06-02 | 開始されました | Jefferies | Hold |
| 2016-02-29 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-02-29 | 開始されました | JP Morgan | Neutral |
| 2016-02-29 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Editas Medicine Inc (EDIT) 最新ニュース
Editas Medicine stock upgraded to Buy by BofA Securities - Investing.com Canada
EDIT (Editas Medicine) Price-to-Operating-Cash-Flow : (As of Nov. 22, 2024) - GuruFocus.com
Editas Medicine FY2024 EPS Forecast Lifted by Zacks Research - MarketBeat
EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus.com
Little Excitement Around Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues As Shares Take 34% Pounding - Simply Wall St
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y - MSN
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat
Editas Medicine stock hits 52-week low at $2.7 amid market challenges - Investing.com India
Editas Medicine's SWOT analysis: gene editing stock faces pivotal phase By Investing.com - Investing.com Australia
Editas Medicine's SWOT analysis: gene editing stock faces pivotal phase - Investing.com
Cantor Fitzgerald Expects Lower Earnings for Editas Medicine - MarketBeat
FY2024 EPS Estimate for Editas Medicine Raised by Analyst - MarketBeat
Vertex Pharmaceutic (VRTX-Q) QuotePress Release - The Globe and Mail
TSX Real Estate Capped Index (TTRE) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail
TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Bristol-Myers Squibb Company (BMY-N) QuotePress Release - The Globe and Mail
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
FY2024 EPS Estimate for Editas Medicine Lifted by Analyst - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Editas Medicine upgraded at Evercore on CRISPR platform - Seeking Alpha
Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire
Editas Medicine to Present at 3 Major Healthcare Investor Conferences | EDIT Stock | EDIT Stock News - StockTitan
Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week - Simply Wall St
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% - Yahoo Finance
Editas downgraded to market perform by Raymond James - MSN
Editas Medicine (FRA:8EM) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
Chardan Capital Reiterates Buy Rating for Editas Medicine (NASDAQ:EDIT) - MarketBeat
Editas Medicine Buy rating and $12 target reaffirmed by Chardan - Investing.com UK
Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT) - StreetInsider.com
Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty - GuruFocus.com
Editas Medicine maintains Perform rating at Oppenheimer By Investing.com - Investing.com UK
Royal Bank of Canada Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $5.00 - MarketBeat
Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results, Hits Expectations - MarketBeat
Editas Medicine target cut to $5 by Barclays on strategic outlook - Investing.com Canada
Editas Medicine Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Editas Medicine (EDIT) PT Lowered to $5 at Barclays - StreetInsider.com
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates - MSN
Truist cuts Editas Medicine target to $8, keeps buy rating By Investing.com - Investing.com Canada
Editas Medicine Reports Q3 2024 Results and Developments - TipRanks
Editas: Q3 Earnings Snapshot - The Washington Post
Editas Medicine (EDIT) PT Lowered to $5 at RBC Capital - StreetInsider.com
Editas downgraded to market perform by Raymond James (NASDAQ:EDIT) - Seeking Alpha
Editas Medicine (NASDAQ:EDIT) Downgraded by Raymond James to "Market Perform" - MarketBeat
Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities - StreetInsider.com
Editas Medicine earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
Editas Medicine Announces Third Quarter 2024 Results and Business Updates - The Manila Times
Editas Medicine Inc (EDIT) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
2.08%
大文字化:
|
ボリューム (24 時間):